Get the Stockscreener App
253.87
0.39%
-1.00
Jazz Pharmaceuticals Plc stock is traded at $253.87, with a volume of 538.23K.
It is down -0.39% in the last 24 hours and up +10.45% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$254.87
Open:
$255.825
24h Volume:
538.23K
Relative Volume:
0.61
Market Cap:
$15.95B
Revenue:
$4.44B
Net Income/Loss:
$29.49M
P/E Ratio:
-13,797.28
EPS:
-0.0184
Net Cash Flow:
$1.19B
1W Performance:
+2.56%
1M Performance:
+10.45%
6M Performance:
+50.48%
1Y Performance:
+115.13%
1-Day Range:
$250.27
$256.75
1-Week Range:
$242.11
$256.75
52-Week Range:
$105.00
$256.75
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
253.87 | 15.95B | 4.44B | 29.49M | 1.19B | -0.0184 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Resumed | Raymond James | Outperform |
| Feb-27-26 | Initiated | Barclays | Overweight |
| Nov-24-25 | Downgrade | UBS | Buy → Neutral |
| Jul-15-25 | Initiated | Deutsche Bank | Buy |
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Renaissance Technologies LLC Sells 17,400 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
JAZZ|Jazz Pharmaceuticals PLC|Price:253.870|Chg%:-1.000 - TradingKey
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Aristotle Capital Management LLC - MarketBeat
Jazz Pharmaceuticals Reports Outcomes of 2026 Annual General Meeting with Strong Shareholder Backing - Kalkine Media
Is JAZZ Still the Best Cannabis Stock After Federal Rescheduling? - Yahoo Finance UK
Jazz Pharmaceuticals (NASDAQ: JAZZ) posts full 2026 AGM voting results - Stock Titan
Jazz Pharmaceuticals PLC $JAZZ is Systematic Financial Management LP's 5th Largest Position - MarketBeat
Jazz Pharmaceuticals plc (JAZZ) Stock Forecasts - Yahoo Finance
Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Globeflex Capital L P - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Position Boosted by California Public Employees Retirement System - MarketBeat
Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history - Yahoo Finance UK
SEB Asset Management AB Purchases New Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Dimensional Fund Advisors LP - MarketBeat
Jazz Pharmaceuticals stock hits all-time high at 250.85 USD By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals (NASDAQ:JAZZ) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Jazz Pharmaceuticals stock hits all-time high at 250.85 USD - Investing.com
Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Principal Financial Group Inc. Increases Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals sets Aug. 3 webcast after market close - Stock Titan
Needham & Company LLC Raises Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $282.00 - MarketBeat
JAZZ Maintains Buy Rating -- Price Target Raised to $282 by Needham - GuruFocus
Did Jazz’s Sleep and Oncology Pipeline Momentum Just Shift Jazz Pharmaceuticals' (JAZZ) Investment Narrative? - simplywall.st
Jazz Pharmaceuticals (JAZZ) Q1 2026 earnings summary - Quartr
Jazz Pharmaceuticals (JAZZ) Stock Still Looks Like A Bargain After A 119% Run - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Refocuses Its Sleep Franchise, Is The Stock Still Cheap? - Yahoo Finance
JAZZ Initiates Coverage On Canaccord Genuity -- Price Target Ann - GuruFocus
JAZZ Initiates Coverage On Canaccord Genuity -- Price Target Announces $290 - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
JAZZ PHARMACEUTICALS PLC : CANACCORD GENUITY INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $290 - Bitget
Is Jazz Pharmaceuticals (JAZZ) Still Undervalued On Its Oncology And Neuroscience Growth Story? - simplywall.st
JAZZ Maintains Overweight Rating by Barclays -- Price Target Raised to $260 - GuruFocus
JAZZ Maintained by Wells Fargo -- Price Target Raised to $285 - GuruFocus
Micron To Rally Around 87%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Jazz Pharmaceuticals (JAZZ) Proxy filing Summary - Quartr
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: Strong Buy Ratings and Potential Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
JAZZ Maintained by Deutsche Bank -- Price Target Raised to $270 - GuruFocus
Jazz Patent Suit Over Xyrem Survives Dismissal In NJ - Law360
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - TradingView
Jazz Pharmaceuticals (JAZZ) Q4 2025 earnings summary - Quartr
JAZZ Maintains Rating by Truist Securities -- Price Target Lowered to $254 - GuruFocus
Sleep Apnea Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Apnimed, Eli Lilly, Incannex Healthcare, Axsome Therapeutics, Jazz Pharma, Bioprojet - Barchart.com
Jazz Pharmaceuticals (JAZZ) director Cozadd sells 6,000 shares via 10b5-1 trade - Stock Titan
Jazz Pharmaceuticals Holds Steady Near Resistance as Volume Patterns Signal CautionQuality Factor - dars.gov.et
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: Growth Potential with a Strategic Focus in Biotechnology - DirectorsTalk Interviews
Jazz Pharmaceuticals PLC at TD Cowen Oncology Innovation Summit (Virtual) Transcript - GuruFocus
JAZZJazz Pharmaceuticals plc Options - Finviz
Jazz Pharmaceuticals (JAZZ) Breakout Keeps Valuation In Focus Following Zepzelca Setback And Ziihera Hopes - simplywall.st
Jazz Pharmaceuticals (JAZZ) EVP reports RSU tax withholding and retains 47,911 shares - Stock Titan
Jazz Pharmaceuticals (JAZZ) CEO shares withheld to cover RSU tax obligations - Stock Titan
Jazz Pharmaceuticals (JAZZ) EVP Iannone reports RSU tax-withholding share disposition - Stock Titan
Jazz Pharmaceuticals (JAZZ) insider RSU tax withholding detailed - Stock Titan
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):